Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
GM

NYSE · GMAB

Genmab A/S

Healthcare · Biotechnology

$37.07

Up+$1.02 (+2.83%)

Updated Oct 10, 2026, 7:29 PM

SID Score

7.5/10

Composite research score

Smart Money

51/100

Neutral

Market cap
19.89B
P/E ratio
14.56
Dividend yield
0.00%
52-week range
$23.62 – $40.17
Volume
2.33M
Avg. volume
2.09M

Price performance · GMAB

GMAB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

GMAB closed at $37.07 after 21 trading sessions, up 14.17% for the selected period.

Last close
$37.07
Period change
+14.17%
Period low
$32.47
Period high
$38.48
Daily close
View OHLC price history
GMAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$36.55$37.15$36.33$37.072.33M
Oct 8, 2026$36.175$36.285$35.09$36.054.3M
Oct 7, 2026$37.28$37.87$36.27$36.654.25M
Oct 6, 2026$39.11$39.15$37.07$37.806.6M
Oct 5, 2026$35.09$40.17$35.02$38.4812.4M
Oct 2, 2026$34.39$35.02$33.725$34.755.44M
Oct 1, 2026$35.25$35.80$34.515$34.556.38M
Sep 30, 2026$35.72$35.905$35.37$35.6755.15M
Sep 29, 2026$34.94$35.64$34.89$35.573.83M
Sep 28, 2026$34.76$35.70$34.63$35.362.79M
Sep 25, 2026$34.95$35.47$34.70$35.323.58M
Sep 24, 2026$34.69$35.03$34.36$34.832.51M
Sep 23, 2026$35.39$35.66$34.605$34.752.51M
Sep 22, 2026$34.46$35.295$34.37$35.222.3M
Sep 21, 2026$34.70$34.865$34.36$34.691.58M
Sep 18, 2026$34.92$35.15$34.715$34.742.71M
Sep 17, 2026$34.28$34.77$34.22$34.5352.7M
Sep 16, 2026$34.36$34.63$34.05$34.402.89M
Sep 15, 2026$32.34$34.185$32.34$34.153.09M
Sep 14, 2026$32.79$32.96$32.52$32.651.41M
Sep 11, 2026$32.45$32.70$32.27$32.471.39M

Latest GMAB news

The latest Smart Investors Daily articles mentioning GMAB.

Stock researchCompany · Overview

GMAB research

Overview

Company profile and research snapshot.

Company profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.25
Implied upside
—
Analysts
—
GMAB recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 23, 2026JYSKE BANKBuy—
Sep 14, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Aug 31, 2026BNP PARIBASOutperform—
Aug 7, 2026DNB CARNEGIEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 3, 2026

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

COPENHAGEN, Denmark, October 03, 2026--Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five compl

Yahoo · Oct 2, 2026

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited (“Darwin”) has informed us that, as of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, co

Yahoo · Sep 27, 2026

Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s vice president and head of investor relations. Carlsen said

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By